Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus
Journal
Swiss Medical Weekly
Volume
144
Pages
w13906
Mesh terms
Ankle Fractures; Anticoagulants, adverse effects; Darunavir; Drug Interactions; Gastrointestinal Hemorrhage, chemically induced; HIV Infections, drug therapy; HIV Protease Inhibitors, therapeutic use; Humans; Male; Middle Aged; Morpholines, adverse effects; Ritonavir, therapeutic use; Rivaroxaban; Sulfonamides, therapeutic use; Thiophenes, adverse effects
Abstract
The use of rivaroxaban in fixed dosing regimens without need for routine coagulation monitoring may lead to the misconception that there is a minimal risk of drug-drug interactions. We describe the case of a patient infected with human immunodeficiency virus (HIV) on salvage therapy who developed gastrointestinal bleeding while receiving the standard dose of rivaroxaban for the prevention of venous thromboembolism after surgery. This case clearly sends a warning that protease inhibitors should not be co-administered with rivaroxaban. Furthermore, it highlights the importance of clinicians' caution about potential drug-drug interactions.
